[A25-147] Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V
Last updated 17.02.2026
Project no.:
A25-147
Commission:
Commission awarded on 17.11.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of symptomatic, inoperable plexiform neurofibromas in adult patients with neurofibromatosis type 1
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-147
| Project no. | Title | Status |
|---|---|---|
| A25-146 | Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G23-14 | Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |